OptimizeRx Corp. (NASDAQ:OPRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
OptimizeRx Corp. (NASDAQ:OPRX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the eleven ratings firms that are presently covering the firm, MarketBeat.com reports. One...
MarketBeat·7h ago
More News
OptimizeRx (NASDAQ:OPRX) Cut to "Hold" at Zacks Research
Zacks Research lowered shares of OptimizeRx from a "strong-buy" rating to a "hold" rating in a report on Monday...
MarketBeat·2d ago
Wall Street Zen Upgrades OptimizeRx (NASDAQ:OPRX) to "Strong-Buy"
Wall Street Zen raised OptimizeRx from a "buy" rating to a "strong-buy" rating in a research note on Sunday...
MarketBeat·5d ago
OptimizeRx (NASDAQ:OPRX) Cut to "Buy" at Wall Street Zen
Wall Street Zen downgraded OptimizeRx from a "strong-buy" rating to a "buy" rating in a research report on Saturday...
MarketBeat·13d ago
Connor Clark & Lunn Investment Management Ltd. Makes New Investment in OptimizeRx Corp. $OPRX
Connor Clark & Lunn Investment Management Ltd. bought a new stake in OptimizeRx Corp. (NASDAQ:OPRX - Free Report) in the second quarter, according to its most recent filing with the Securities...
MarketBeat·28d ago
P.A.W. Capital Corp Invests $675,000 in OptimizeRx Corp. $OPRX
P.A.W. Capital Corp purchased a new position in OptimizeRx Corp. (NASDAQ:OPRX - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and...
MarketBeat·29d ago
New Strong Buy Stocks for Nov. 17: ROKU, AVPT, and More
ROKU, AVPT, ETOR, NRIM and OPRX have been added to the Zacks Rank #1 (Strong Buy) List on November 17, 2025.
Zacks·1mo ago
Los Angeles Capital Management LLC Makes New $349,000 Investment in OptimizeRx Corp. $OPRX
Los Angeles Capital Management LLC purchased a new stake in OptimizeRx Corp. (NASDAQ:OPRX - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The...
OptimizeRx (NASDAQ:OPRX) Issues Earnings Results, Beats Expectations By $0.17 EPS
OptimizeRx (NASDAQ:OPRX - Get Free Report) released its quarterly earnings results on Thursday. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.03 by $0.17...